---
input_text: "Blood transfusion for preventing primary and secondary stroke in people
  with sickle cell disease. BACKGROUND: Sickle cell disease is one of the commonest
  severe monogenic disorders in the world, due to the inheritance of two abnormal
  haemoglobin (beta globin) genes. Sickle cell disease can cause severe pain, significant
  end-organ damage, pulmonary complications, and premature death. Stroke affects around
  10% of children with sickle cell anaemia (HbSS). Chronic blood transfusions may
  reduce the risk of vaso-occlusion and stroke by diluting the proportion of sickled
  cells in the circulation. This is an update of a Cochrane Review first published
  in 2002, and last updated in 2017. OBJECTIVES: To assess risks and benefits of chronic
  blood transfusion regimens in people with sickle cell disease for primary and secondary
  stroke prevention (excluding silent cerebral infarcts). SEARCH METHODS: We searched
  for relevant trials in the Cochrane Library, MEDLINE (from 1946), Embase (from 1974),
  the Transfusion Evidence Library (from 1980), and ongoing trial databases; all searches
  current to 8 October 2019. We searched the Cochrane Cystic Fibrosis and Genetic
  Disorders Group Haemoglobinopathies Trials Register: 19 September 2019. SELECTION
  CRITERIA: Randomised controlled trials comparing red blood cell transfusions as
  prophylaxis for stroke in people with sickle cell disease to alternative or standard
  treatment. There were no restrictions by outcomes examined, language or publication
  status. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial eligibility
  and the risk of bias and extracted data. MAIN RESULTS: We included five trials (660
  participants) published between 1998 and 2016. Four of these trials were terminated
  early. The vast majority of participants had the haemoglobin (Hb)SS form of sickle
  cell disease. Three trials compared regular red cell transfusions to standard care
  in primary prevention of stroke: two in children with no previous long-term transfusions;
  and one in children and adolescents on long-term transfusion. Two trials compared
  the drug hydroxyurea (hydroxycarbamide) and phlebotomy to long-term transfusions
  and iron chelation therapy: one in primary prevention (children); and one in secondary
  prevention (children and adolescents). The quality of the evidence was very low
  to moderate across different outcomes according to GRADE methodology. This was due
  to the trials being at a high risk of bias due to lack of blinding, indirectness
  and imprecise outcome estimates. Red cell transfusions versus standard care Children
  with no previous long-term transfusions Long-term transfusions probably reduce the
  incidence of clinical stroke in children with a higher risk of stroke (abnormal
  transcranial doppler velocities or previous history of silent cerebral infarct),
  risk ratio 0.12 (95% confidence interval 0.03 to 0.49) (two trials, 326 participants),
  moderate quality evidence. Long-term transfusions may: reduce the incidence of other
  sickle cell disease-related complications (acute chest syndrome, risk ratio 0.24
  (95% confidence interval 0.12 to 0.48)) (two trials, 326 participants); increase
  quality of life (difference estimate -0.54, 95% confidence interval -0.92 to -0.17)
  (one trial, 166 participants); but make little or no difference to IQ scores (least
  square mean: 1.7, standard error 95% confidence interval -1.1 to 4.4) (one trial,
  166 participants), low quality evidence. We are very uncertain whether long-term
  transfusions: reduce the risk of transient ischaemic attacks, Peto odds ratio 0.13
  (95% confidence interval 0.01 to 2.11) (two trials, 323 participants); have any
  effect on all-cause mortality, no deaths reported (two trials, 326 participants);
  or increase the risk of alloimmunisation, risk ratio 3.16 (95% confidence interval
  0.18 to 57.17) (one trial, 121 participants), very low quality evidence. Children
  and adolescents with previous long-term transfusions (one trial, 79 participants)
  We are very uncertain whether continuing long-term transfusions reduces the incidence
  of: stroke, risk ratio 0.22 (95% confidence interval 0.01 to 4.35); or all-cause
  mortality, Peto odds ratio 8.00 (95% confidence interval 0.16 to 404.12), very low
  quality evidence. Several review outcomes were only reported in one trial arm (sickle
  cell disease-related complications, alloimmunisation, transient ischaemic attacks).
  The trial did not report neurological impairment, or quality of life. Hydroxyurea
  and phlebotomy versus red cell transfusions and chelation Neither trial reported
  on neurological impairment, alloimmunisation, or quality of life. Primary prevention,
  children (one trial, 121 participants) Switching to hydroxyurea and phlebotomy may
  have little or no effect on liver iron concentrations, mean difference -1.80 mg
  Fe/g dry-weight liver (95% confidence interval -5.16 to 1.56), low quality evidence.
  We are very uncertain whether switching to hydroxyurea and phlebotomy has any effect
  on: risk of stroke (no strokes); all-cause mortality (no deaths); transient ischaemic
  attacks, risk ratio 1.02 (95% confidence interval 0.21 to 4.84); or other sickle
  cell disease-related complications (acute chest syndrome, risk ratio 2.03 (95% confidence
  interval 0.39 to 10.69)), very low quality evidence. Secondary prevention, children
  and adolescents (one trial, 133 participants) Switching to hydroxyurea and phlebotomy
  may: increase the risk of sickle cell disease-related serious adverse events, risk
  ratio 3.10 (95% confidence interval 1.42 to 6.75); but have little or no effect
  on median liver iron concentrations (hydroxyurea, 17.3 mg Fe/g dry-weight liver
  (interquartile range 10.0 to 30.6)); transfusion 17.3 mg Fe/g dry-weight liver (interquartile
  range 8.8 to 30.7), low quality evidence. We are very uncertain whether switching
  to hydroxyurea and phlebotomy: increases the risk of stroke, risk ratio 14.78 (95%
  confidence interval 0.86 to 253.66); or has any effect on all-cause mortality, Peto
  odds ratio 0.98 (95% confidence interval 0.06 to 15.92); or transient ischaemic
  attacks, risk ratio 0.66 (95% confidence interval 0.25 to 1.74), very low quality
  evidence. AUTHORS' CONCLUSIONS: There is no evidence for managing adults, or children
  who do not have HbSS sickle cell disease. In children who are at higher risk of
  stroke and have not had previous long-term transfusions, there is moderate quality
  evidence that long-term red cell transfusions reduce the risk of stroke, and low
  quality evidence they also reduce the risk of other sickle cell disease-related
  complications. In primary and secondary prevention of stroke there is low quality
  evidence that switching to hydroxyurea with phlebotomy has little or no effect on
  the liver iron concentration. In secondary prevention of stroke there is low-quality
  evidence that switching to hydroxyurea with phlebotomy increases the risk of sickle
  cell disease-related events. All other evidence in this review is of very low quality."
raw_completion_output: |-
  primary_disease: Sickle cell disease
  medical_actions: Blood transfusion;Chronic blood transfusions;Red cell transfusions;Switching to hydroxyurea and phlebotomy
  symptoms: Severe pain;End-organ damage;Pulmonary complications;Premature death;Stroke;Acute chest syndrome;Transient ischaemic attacks;Sickle cell disease-related serious adverse events
  chemicals: Hydroxyurea;Hydroxycarbamide
  action_annotation_relationships: Blood transfusion PREVENTS stroke IN Sickle cell disease;Chronic blood transfusions PREVENTS stroke IN Sickle cell disease;Red cell transfusions PREVENTS stroke IN Sickle cell disease;Red cell transfusions TREATS Severe pain IN Sickle cell disease;Red cell transfusions TREATS End-organ damage IN Sickle cell disease;Red cell transfusions TREATS Pulmonary complications IN Sickle cell disease;Red cell transfusions PREVENTS Premature death IN Sickle cell disease;Red cell transfusions TREATS Acute chest syndrome IN Sickle cell disease;Switching to hydroxyurea and phlebotomy (with Hydroxyurea) TREATS Liver iron concentrations IN Sickle cell disease;Switching to hydroxyurea and phlebotomy (with Hydroxyurea) INCREASES risk of Sickle cell disease-related serious adverse events IN Sickle cell disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Switching to hydroxyurea and phlebotomy (with Hydroxyurea) INCREASES risk of Sickle cell disease-related serious adverse events IN Sickle cell disease

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - MAXO:0000756
    - Chronic blood transfusions
    - Red cell transfusions
    - Switching to hydroxyurea and phlebotomy
  symptoms:
    - Severe pain
    - End-organ damage
    - Pulmonary complications
    - Premature death
    - HP:0001297
    - Acute chest syndrome
    - HP:0002326
    - Sickle cell disease-related serious adverse events
  chemicals:
    - CHEBI:44423
    - CHEBI:44423
  action_annotation_relationships:
    - subject: MAXO:0000756
      predicate: PREVENTS
      object: HP:0001297
      qualifier: MONDO:0011382
    - subject: Chronic blood transfusions
      predicate: PREVENTS
      object: HP:0001297
      qualifier: MONDO:0011382
    - subject: Red cell transfusions
      predicate: PREVENTS
      object: HP:0001297
      qualifier: MONDO:0011382
    - subject: <transfusions>
      predicate: <TREATS>
      object: <Severe pain>
      qualifier: <Sickle cell disease>
      subject_extension: <Red cell>
    - subject: Red cell transfusions
      predicate: TREATS
      object: End-organ damage
      qualifier: MONDO:0011382
    - subject: Red cell transfusions
      predicate: TREATS
      object: Pulmonary complications
      qualifier: MONDO:0011382
    - subject: Red cell transfusions
      predicate: PREVENTS
      object: Premature death
      qualifier: MONDO:0011382
    - subject: Red cell transfusions
      predicate: TREATS
      object: Acute chest syndrome
      qualifier: MONDO:0011382
    - subject: Switching to hydroxyurea and phlebotomy
      predicate: TREATS
      object: Liver iron concentrations
      qualifier: MONDO:0011382
      subject_qualifier: with Hydroxyurea
      subject_extension: CHEBI:44423
    - subject: Switching to hydroxyurea and phlebotomy
      predicate: INCREASES
      object: Sickle cell disease-related serious adverse events
      qualifier: MONDO:0011382
      subject_qualifier: with Hydroxyurea
      subject_extension: CHEBI:44423
named_entities:
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: MAXO:0000457
    label: Pain Management
  - id: HP:0012531
    label: Pain
  - id: HP:0000739
    label: anxiety
  - id: MONDO:0005812
    label: Influenza
  - id: MAXO:0001017
    label: vaccination
  - id: MAXO:0000756
    label: transfusion
  - id: MONDO:0018881
    label: Myelodysplasia
  - id: MONDO:0000984
    label: Thalassemia
  - id: MONDO:0018373
    label: avascular necrosis (AVN)
  - id: MAXO:0009047
    label: total hip replacement (THR)
  - id: HP:0010885
    label: avascular necrosis
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: CHEBI:131923
    label: Salubrinal
  - id: MAXO:0000068
    label: Transplantation
  - id: CHEBI:44423
    label: hydroxyurea
  - id: MONDO:0003664
    label: Haemolytic Anaemias
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0025464
    label: Oxidative stress
  - id: MAXO:0001298
    label: therapies
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: HP:0100512
    label: Vitamin D deficiency
  - id: CHEBI:27300
    label: Vitamin D
  - id: CHEBI:28940
    label: Cholecalciferol
  - id: CHEBI:29016
    label: Arginine
  - id: CHEBI:18211
    label: Citrulline
  - id: CHEBI:3638
    label: Chloroquine
  - id: CHEBI:50733
    label: Nutritional supplements
  - id: HP:0012532
    label: Chronic pain
  - id: HP:0000716
    label: Depression
  - id: HP:0012432
    label: Chronic fatigue
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplant (HSCT)
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0007760
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0035088
    label: magnetic resonance imaging (MRI)/magnetic resonance angiography (MRA)
  - id: HP:0002140
    label: ischemic stroke
  - id: HP:0001139
    label: abnormal transcranial Doppler ultrasound (TCD) results
  - id: MONDO:0006079
    label: Acute Chest Syndrome (ACS)
  - id: HP:0001945
    label: Fever
  - id: HP:0002878
    label: Acute respiratory failure
  - id: CHEBI:82594
    label: Ferritin
  - id: HP:0002204
    label: pulmonary embolism
  - id: CHEBI:50249
    label: anticoagulants
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:82557
    label: treosulfan
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000750
    label: conditioning regimens
  - id: MAXO:0000618
    label: fluid replacement therapy
  - id: HP:0001919
    label: acute kidney injury
  - id: CHEBI:63895
    label: Interleukin (IL)-6
  - id: CHEBI:197439
    label: TNFalpha
  - id: MONDO:0005502
    label: Dengue fever
  - id: HP:0003326
    label: myalgia
  - id: HP:0002027
    label: abdominal pain
  - id: HP:0002315
    label: headache
  - id: CHEBI:18050
    label: L-glutamine
  - id: MONDO:0018948
    label: Moyamoya disorder (MMD)
  - id: HP:0001250
    label: seizures
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0012378
    label: Fatigue
  - id: CHEBI:28876
    label: melphalan
  - id: CHEBI:61049
    label: tacrolimus
  - id: CHEBI:44185
    label: methotrexate
  - id: MAXO:0000004
    label: Surgical intervention
  - id: CHEBI:16335
    label: Adenosine
  - id: CHEBI:177467
    label: Opiorphin
  - id: CHEBI:17347
    label: Testosterone
  - id: MAXO:0000149
    label: hematopoietic cell transplantation (HCT)
  - id: HP:0001297
    label: Stroke
  - id: MONDO:0005151
    label: Endocrinopathy
  - id: HP:0004322
    label: short stature
  - id: HP:0000819
    label: diabetes mellitus
  - id: HP:0000135
    label: hypogonadism
  - id: HP:0000938
    label: osteopenia
  - id: HP:0000939
    label: osteoporosis
  - id: HP:0000821
    label: hypothyroidism
  - id: HP:0008163
    label: hypocortisolism
  - id: HP:0000829
    label: hypoparathyroidism
  - id: HP:0000818
    label: Endocrinopathy
  - id: MAXO:0001175
    label: Liver transplantation
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: MONDO:0013730
    label: Acute Graft-versus-Host Disease (GVHD)
  - id: HP:0001903
    label: anemia
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0000083
    label: Kidney failure
  - id: HP:0002617
    label: Vasculopathy
  - id: CHEBI:17303
    label: Morphine
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0031417
    label: rhinorrhea
  - id: HP:0012735
    label: cough
  - id: HP:0025095
    label: sneezing
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:5588
    label: Hemoglobin A (HbA)
  - id: MAXO:0000602
    label: hemodialysis
  - id: HP:0011675
    label: Arrhythmias
  - id: HP:0012418
    label: Hypoxia
  - id: HP:0001907
    label: thromboembolism
  - id: CHEBI:114786
    label: Sodium metabisulphite
  - id: CHEBI:17790
    label: Methanol
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:59229
    label: GnRH antagonist
  - id: CHEBI:63533
    label: GnRH agonist
  - id: MAXO:0001490
    label: platelet transfusions
  - id: CHEBI:9168
    label: sirolimus
  - id: MAXO:0009003
    label: Preimplantation genetic testing
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: HP:0100602
    label: Preeclampsia
  - id: HP:0001622
    label: Preterm birth
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0100806
    label: Sepsis
  - id: CHEBI:41879
    label: Dexamethasone
  - id: MAXO:0010030
    label: Bone marrow transplantation
  - id: HP:0001878
    label: Hemolytic anemia
  - id: HP:0002904
    label: hyperbilirubinemia
  - id: CHEBI:32026
    label: poloxamer 188
  - id: CHEBI:81579
    label: erythropoietin
  - id: MONDO:0004745
    label: Priapism
  - id: CHEBI:44915
    label: Propofol
  - id: CHEBI:28304
    label: Heparin
  - id: CHEBI:9449
    label: Terbutaline
  - id: MAXO:0000503
    label: Mechanical ventilation
  - id: MAXO:0000600
    label: Renal replacement therapy
  - id: HP:0006554
    label: Acute liver failure
  - id: HP:0100626
    label: End-stage liver disease
  - id: MONDO:0004992
    label: cancer
  - id: MONDO:0012268
    label: AIDS
  - id: MONDO:0003847
    label: genetic disorders
  - id: CHEBI:68554
    label: deferiprone
  - id: CHEBI:49005
    label: deferasirox
  - id: CHEBI:4356
    label: deferoxamine
  - id: CHEBI:33281
    label: antibiotics
  - id: MONDO:0011549
    label: Hyperhaemolysis syndrome (HHS)
  - id: CHEBI:29007
    label: Ceftriaxone
  - id: CHEBI:2955
    label: Azithromycin
  - id: CHEBI:2549
    label: Albuterol
  - id: CHEBI:35341
    label: steroid
  - id: HP:0004870
    label: chronic hemolytic anemia
  - id: HP:0100543
    label: cognitive dysfunction
  - id: MONDO:0019402
    label: Thalassemia Major
  - id: MONDO:0020380
    label: sickle cell anemia (SCA)
  - id: HP:0002754
    label: Osteomyelitis
  - id: HP:0001649
    label: Tachycardia
  - id: HP:0025143
    label: Chills
  - id: HP:0000790
    label: Hematuria
  - id: MONDO:0002050
    label: Depression
  - id: CHEBI:6754
    label: Meperidine
  - id: HP:0000789
    label: infertility
  - id: HP:0008209
    label: premature ovarian insufficiency
  - id: MONDO:0005096
    label: Sickle Cell Crisis (SCC)
  - id: HP:0002860
    label: SCC
  - id: CHEBI:30413
    label: Heme
  - id: CHEBI:15854
    label: Quinine
  - id: CHEBI:17245
    label: Carbon monoxide
  - id: CHEBI:17033
    label: Biliverdin
  - id: HP:0030858
    label: addiction
  - id: CHEBI:50825
    label: Gold nanoparticles (Au NPs)
  - id: CHEBI:35255
    label: chloroform
  - id: CHEBI:27750
    label: ethyl acetate
  - id: CHEBI:4775
    label: ellagic acid
  - id: CHEBI:13193
    label: 3,3',4'-tri-O-methyl ellagic acid (A)
  - id: CHEBI:27560
    label: 3,3'-di-O- methyl ellagic acid (B)
  - id: MONDO:0004995
    label: cardiovascular disease
  - id: CHEBI:125354
    label: Plerixafor
  - id: CHEBI:6129
    label: Ketorolac
  - id: CHEBI:32599
    label: Magnesium sulfate
  - id: CHEBI:6128
    label: Ketoprofen
  - id: CHEBI:5855
    label: Ibuprofen
  - id: CHEBI:6807
    label: Methadone
  - id: CHEBI:16480
    label: Nitric oxide
  - id: CHEBI:6888
    label: Methylprednisolone
  - id: MONDO:0016264
    label: Autoimmune hepatitis (AIH)
  - id: CHEBI:8378
    label: prednisolone
  - id: CHEBI:2948
    label: azathioprine
  - id: MAXO:0001128
    label: Folic Acid Supplementation
  - id: CHEBI:27470
    label: Folic Acid
  - id: CHEBI:35143
    label: Hemoglobin
  - id: MONDO:0005136
    label: Malaria
  - id: HP:0006517
    label: Poor academic performance (PAP)
  - id: MONDO:0800385
    label: Iron overload
  - id: CHEBI:63005
    label: sodium nitrate
  - id: CHEBI:29321
    label: sodium nitroprusside
  - id: CHEBI:17632
    label: nitrate
  - id: HP:0002719
    label: Susceptibility to infections
  - id: HP:0005541
    label: Sickle Cell Nephropathy (SCN)
  - id: HP:0003774
    label: End Stage Renal Disease (ESRD)
  - id: CHEBI:138181
    label: IL8
  - id: MAXO:0000487
    label: Clinical assessment
  - id: CHEBI:55379
    label: Cyclosporine (CsA)
  - id: CHEBI:4031
    label: Cyclosporine
  - id: MAXO:0000336
    label: bone marrow biopsy
  - id: HP:0033667
    label: altered mental status
  - id: HP:0001876
    label: pancytopenia
  - id: HP:0032008
    label: fat embolism
  - id: HP:0001394
    label: Cirrhosis
  - id: HP:0000952
    label: jaundice
  - id: HP:0002240
    label: hepatomegaly
  - id: HP:0001744
    label: splenomegaly
  - id: MONDO:0019180
    label: Hereditary Hemorrhagic Telangiectasia (HHT)
  - id: CHEBI:5790
    label: hydromorphone
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:35623
    label: anticonvulsants
  - id: CHEBI:35469
    label: antidepressants
  - id: CHEBI:6121
    label: ketamine
  - id: HP:0010972
    label: ineffective erythropoiesis
  - id: HP:0003077
    label: Hyperlipidemia
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0012330
    label: Pyelonephritis
  - id: HP:0001511
    label: Intrauterine growth restriction
  - id: HP:0003811
    label: Neonatal death
  - id: MAXO:0001039
    label: Cholecystectomy
  - id: HP:0001268
    label: cognitive decline
  - id: MONDO:0002280
    label: Anemia
  - id: HP:0001931
    label: Hypochromic anemia
  - id: CHEBI:18248
    label: Iron
  - id: HP:0001935
    label: microcytic anemia
  - id: HP:0002516
    label: Intracranial hypertension
  - id: CHEBI:16526
    label: Carbon dioxide (CO2)
  - id: HP:0012864
    label: abnormal sperm morphology
  - id: CHEBI:28300
    label: glutamine
  - id: CHEBI:18237
    label: Glutamic acid
  - id: CHEBI:27266
    label: Valine
  - id: CHEBI:17334
    label: Penicillin
  - id: CHEBI:22315
    label: Alkaloids
  - id: CHEBI:26848
    label: Tannins
  - id: CHEBI:22580
    label: Anthraquinones
  - id: CHEBI:15889
    label: Sterols
  - id: CHEBI:26605
    label: Saponins
  - id: CHEBI:26195
    label: Polyphenols
  - id: CHEBI:26873
    label: Terpenoids
  - id: CHEBI:15882
    label: Phenols
  - id: CHEBI:83970
    label: Cardiac glycosides
  - id: HP:0000822
    label: hypertension
  - id: HP:0002664
    label: cancer
  - id: CHEBI:51371
    label: Muscle relaxant
  - id: HP:0003394
    label: muscle spasms
  - id: CHEBI:35718
    label: Antifungal
  - id: MAXO:0010203
    label: Echocardiography
  - id: HP:0200023
    label: Priapism
  - id: HP:0000823
    label: Pubertal delay
  - id: HP:0000670
    label: Tooth decay
  - id: HP:0000805
    label: Enuresis
  - id: HP:0001638
    label: Cardiomyopathy
  - id: HP:0030157
    label: Flank pain
  - id: HP:0100749
    label: Chest pain
  - id: MONDO:0005570
    label: Hematological diseases
  - id: HP:0004444
    label: Spherocytosis
  - id: HP:0001028
    label: Hemangioma
  - id: MONDO:0005380
    label: Avascular necrosis
  - id: MAXO:0000640
    label: Corticosteroid treatment
  - id: HP:0002829
    label: Joint pain
  - id: MONDO:0006502
    label: Severe COVID-19 with acute respiratory distress syndrome (ARDS) in a sickle
      cell disease adult patient
  - id: CHEBI:8093
    label: Phenylephrine
  - id: HP:0002902
    label: Hyponatremia
  - id: CHEBI:26708
    label: Sodium
  - id: HP:0012649
    label: Increased inflammatory response
  - id: MONDO:0005354
    label: chronic hepatitis C
  - id: CHEBI:85083
    label: sofosbuvir
  - id: CHEBI:63580
    label: ribavirin
  - id: CHEBI:82977
    label: daclatasvir
  - id: CHEBI:85089
    label: ledipasvir
  - id: CHEBI:133009
    label: velpatasvir
  - id: CHEBI:132975
    label: grazoprevir
  - id: CHEBI:132967
    label: elbasvir
  - id: CHEBI:133008
    label: sofosbuvir and velpatasvir
  - id: CHEBI:71029
    label: Serum fructosamine (SF)
  - id: CHEBI:24103
    label: fructosamine
  - id: MONDO:0005015
    label: Sickle cell disease and diabetes mellitus (DM)
  - id: MONDO:0017291
    label: Reversible Cerebral Vasoconstriction Syndrome
  - id: CHEBI:36751
    label: PCA
  - id: CHEBI:81351
    label: Activin A
  - id: HP:0002326
    label: Transient ischaemic attacks
